NCT06970223View on ClinicalTrials.gov

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

July 30, 2025

Study Completion Date

July 10, 2026

Conditions
HIV Infections
Interventions
DRUG

Cabotegravir long-acting

A single CAB LA injection administered intramuscularly.

DRUG

Lenacapavir long-acting

Two LEN LA injections administered subcutaneously.

Trial Locations (1)

90712

GSK Investigational Site, Long Beach

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY